Japan's MHLW gives nods for Remicade, VFend, Tracleer, INOflo new indications

Japan's Ministry of Health, Labor and Welfare last week gave the nod to several new drug indications, including Mitsubishi Tanabe's Remicade for intravenous use and indications of entero-Behcet, neuro-Behcet and vasculo-Behcet diseases when existing treatments are inadequate, a spokesman for the ministry said. The other approved new indications were for Pfizer's ($PFE) VFend, Actelion Pharmaceuticals' ($ATLN) Tracleer, and INO Therapeutics' INOflo. More